Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Biocartis Group

BATS-CHIXE:BCARTB
Snowflake Description

High growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BCARTB
BATS-CHIXE
€198M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry, with a focus on oncology in Belgium and internationally. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • Biocartis Group has significant price volatility in the past 3 months.
BCARTB Share Price and Events
7 Day Returns
-1%
BATS-CHIXE:BCARTB
-3%
GB Medical Equipment
-5.4%
GB Market
1 Year Returns
-69.3%
BATS-CHIXE:BCARTB
-3.9%
GB Medical Equipment
-25.2%
GB Market
BCARTB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biocartis Group (BCARTB) -1% -30.9% -39.5% -69.3% -67.1% -
GB Medical Equipment -3% -19.8% -22.9% -3.9% -4.6% 15.3%
GB Market -5.4% -20.6% -29.1% -25.2% -25.9% -25.1%
1 Year Return vs Industry and Market
  • BCARTB underperformed the Medical Equipment industry which returned -3.9% over the past year.
  • BCARTB underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -25.2% over the past year.
Price Volatility
BCARTB
Industry
5yr Volatility vs Market

Value

 Is Biocartis Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biocartis Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biocartis Group.

BATS-CHIXE:BCARTB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:BCARTB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 6.2%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.85
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.848 (1 + (1- 29%) (83.93%))
1.237
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.24
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.237 * 6.21%)
8.21%

Discounted Cash Flow Calculation for BATS-CHIXE:BCARTB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biocartis Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:BCARTB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.21%)
2020 -30.40 Analyst x1 -28.09
2021 -5.50 Analyst x1 -4.70
2022 30.20 Analyst x1 23.83
2023 60.40 Analyst x1 44.05
2024 89.40 Analyst x1 60.26
2025 111.79 Est @ 25.04% 69.63
2026 131.56 Est @ 17.69% 75.73
2027 148.06 Est @ 12.54% 78.76
2028 161.29 Est @ 8.94% 79.29
2029 171.63 Est @ 6.41% 77.97
Present value of next 10 years cash flows €476.00
BATS-CHIXE:BCARTB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €171.63 × (1 + 0.53%) ÷ (8.21% – 0.53%)
€2,246.85
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €2,246.85 ÷ (1 + 8.21%)10
€1,020.77
BATS-CHIXE:BCARTB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €476.00 + €1,020.77
€1,496.77
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1,496.77 / 56.38
€26.55
BATS-CHIXE:BCARTB Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:BCARTB represents 1.00142x of ENXTBR:BCART
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.00142x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 26.55 x 1.00142
€26.58
Value per share (EUR) From above. €26.58
Current discount Discount to share price of €3.53
= -1 x (€3.53 - €26.58) / €26.58
86.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Biocartis Group is available for.
Intrinsic value
>50%
Share price is €3.53 vs Future cash flow value of €26.58
Current Discount Checks
For Biocartis Group to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Biocartis Group's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Biocartis Group's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biocartis Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biocartis Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:BCARTB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-1.14
ENXTBR:BCART Share Price ** ENXTBR (2020-04-02) in EUR €3.52
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 24.3x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.44x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biocartis Group.

BATS-CHIXE:BCARTB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:BCART Share Price ÷ EPS (both in EUR)

= 3.52 ÷ -1.14

-3.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biocartis Group is loss making, we can't compare its value to the GB Medical Equipment industry average.
  • Biocartis Group is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Biocartis Group's expected growth come at a high price?
Raw Data
BATS-CHIXE:BCARTB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.09x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
74.6%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2.19x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 518 Publicly-Listed Companies 0.97x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biocartis Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biocartis Group's assets?
Raw Data
BATS-CHIXE:BCARTB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €1.49
ENXTBR:BCART Share Price * ENXTBR (2020-04-02) in EUR €3.52
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.84x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.07x
BATS-CHIXE:BCARTB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:BCART Share Price ÷ Book Value per Share (both in EUR)

= 3.52 ÷ 1.49

2.36x

* Primary Listing of Biocartis Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biocartis Group is good value based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Biocartis Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Biocartis Group has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Biocartis Group expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
74.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biocartis Group expected to grow at an attractive rate?
  • Biocartis Group's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Biocartis Group's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Biocartis Group's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:BCARTB Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:BCARTB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 74.6%
BATS-CHIXE:BCARTB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 33.9%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.3%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.4%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.3%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:BCARTB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:BCARTB Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 285 1
2023-12-31 228 1
2022-12-31 136 15 2
2021-12-31 91 -14 3
2020-12-31 50 -23 -52 1
2020-04-03
BATS-CHIXE:BCARTB Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 38 -54 -64
2019-09-30 35 -52 -60
2019-06-30 33 -50 -56
2019-03-31 31 -46 -52
2018-12-31 29 -42 -48
2018-09-30 29 -41 -44
2018-06-30 29 -40 -40
2018-03-31 26 -40 -41
2017-12-31 23 -41 -42
2017-09-30 19 -46 -46
2017-06-30 14 -50 -50
2017-03-31 14 -52 -50

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biocartis Group's earnings are expected to grow significantly at over 20% yearly.
  • Biocartis Group's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:BCARTB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Biocartis Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:BCARTB Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 -0.28 -0.28 -0.28 1.00
2021-12-31 -0.66 -0.66 -0.66 1.00
2020-12-31 -0.93 -0.93 -0.93 1.00
2020-04-03
BATS-CHIXE:BCARTB Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -1.14
2019-09-30 -1.10
2019-06-30 -1.05
2019-03-31 -1.00
2018-12-31 -0.94
2018-09-30 -0.86
2018-06-30 -0.82
2018-03-31 -0.87
2017-12-31 -0.93
2017-09-30 -0.90
2017-06-30 -1.16
2017-03-31 -1.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Biocartis Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Biocartis Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biocartis Group has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Biocartis Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biocartis Group's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biocartis Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Biocartis Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biocartis Group's 1-year growth to the GB Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Biocartis Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biocartis Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:BCARTB Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 37.73 -64.07 32.16
2019-09-30 35.47 -60.07 29.91
2019-06-30 33.21 -56.06 27.57
2019-03-31 30.93 -52.11 25.44
2018-12-31 28.65 -48.15 23.32
2018-09-30 28.76 -43.95 22.25
2018-06-30 28.87 -39.74 21.27
2018-03-31 25.99 -40.85 19.85
2017-12-31 23.11 -41.96 18.43
2017-09-30 18.56 -45.97 17.29
2017-06-30 14.00 -49.98 16.14
2017-03-31 13.89 -49.88 16.15
2016-12-31 13.77 -49.78 16.15
2016-09-30 14.12 -48.22 16.45
2016-06-30 14.48 -46.67 16.75
2016-03-31 14.71 -43.23 16.08
2015-12-31 14.95 -39.80 15.41
2015-09-30 15.02 -34.82 14.09
2015-06-30 15.09 -29.85 12.78
2015-03-31 12.73 -29.22 11.53
2014-12-31 10.37 -28.59 10.28
2013-12-31 11.84 -27.44 8.46

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biocartis Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Biocartis Group has efficiently used its assets last year compared to the GB Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biocartis Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biocartis Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biocartis Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Biocartis Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biocartis Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biocartis Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biocartis Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biocartis Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biocartis Group Company Filings, last reported 3 months ago.

BATS-CHIXE:BCARTB Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 84.48 166.58 178.73
2019-09-30 84.48 166.58 178.73
2019-06-30 123.61 134.97 209.20
2019-03-31 123.61 134.97 209.20
2018-12-31 87.35 17.78 63.54
2018-09-30 87.35 17.78 63.54
2018-06-30 112.66 17.27 91.27
2018-03-31 112.66 17.27 91.27
2017-12-31 132.24 16.76 112.77
2017-09-30 132.24 16.76 112.77
2017-06-30 73.02 16.28 59.04
2017-03-31 73.02 16.28 59.04
2016-12-31 96.89 15.80 83.25
2016-09-30 96.89 15.80 83.25
2016-06-30 91.71 8.03 75.76
2016-03-31 91.71 8.03 75.76
2015-12-31 114.92 7.78 104.09
2015-09-30 114.92 7.78 104.09
2015-06-30 137.02 13.36 128.48
2015-03-31 137.02 13.36 128.48
2014-12-31 20.28 10.60 10.92
2013-12-31 31.96 12.09 29.05
  • Biocartis Group's level of debt (159.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (46.5% vs 159.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Biocartis Group has sufficient cash runway for more than 3 years based on current free cash flow.
  • Unable to confirm if Biocartis Group has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Biocartis Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biocartis Group has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Biocartis Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biocartis Group dividends.
If you bought €2,000 of Biocartis Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biocartis Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biocartis Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:BCARTB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 608 Stocks 5.7%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:BCARTB Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biocartis Group has not reported any payouts.
  • Unable to verify if Biocartis Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biocartis Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biocartis Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Biocartis Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biocartis Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biocartis Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Biocartis Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Herman Verrelst
COMPENSATION €510,000
AGE 45
TENURE AS CEO 2.7 years
CEO Bio

Mr. Herman Verrelst has been Chief Executive Officer of Biocartis Group NV since August 31, 2017. Mr. Verrelst serves as the President of the Board at FOx Diagnostics. He serves as Director of European Operations at Detica Group Holdings (Ireland) Limited and of Norkom Group Plc. He serves as Vice President and General Manager of the Genomics and Clinical Applications Division of Agilent Technologies Inc. and joined in May 2015 as General Manager of the Clinical Applications Division. Mr. Verrelst is an experienced entrepreneur and business manager with a specific background in the set up and management of high-tech companies and university spin-offs. He manages sales and delivery activities for Norkom in Continental Europe. He has 10 years of experience in the areas of risk management and customer intelligence. First he was Research Associate at the K.U.Leuven in Belgium, on advanced pattern recognition techniques for customer profiling and fraud detection, in that time he also provided consulting on the design and implementation of fraud detection systems to international organizations in the financial services and telecommunications sector for 4 years. Mr. Verrelst founded Cartagenia n.v. and served as its Chief Executive Officer. He served as Chief Executive Officer of Medicim. He was co-founder of DATA4s and served as its Chief Executive Officer and Managing Director. He has been a Director of Biocartis Group NV since September 11, 2017. He holds a Masters Degree in Engineering from the K.U.Leuven, Belgium in 1996.

CEO Compensation
  • Herman's compensation has increased whilst company is loss making.
  • Herman's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Biocartis Group management team in years:

3.8
Average Tenure
51
Average Age
  • The tenure for the Biocartis Group management team is about average.
Management Team

Herman Verrelst

TITLE
CEO & Director
COMPENSATION
€510K
AGE
45
TENURE
2.7 yrs

Benoit Devogelaere

TITLE
Chief Technology Officer
AGE
38
TENURE
2.3 yrs

Hilde Eylenbosch

TITLE
Chief Commercial Officer
AGE
55
TENURE
3.5 yrs

Piet Houwen

TITLE
Chief Operating Officer
TENURE
1 yrs

Geert Maertens

TITLE
Chairman of Scientific Advisory Board & Chief Scientific Officer

Renate Degrave

TITLE
Head of IR & Corporate Communications

Susy Spruyt

TITLE
Head of People & Organization
AGE
51
TENURE
5.3 yrs

Erwin Sablon

TITLE
Head of R&D and Alliance Management
AGE
54
TENURE
7.7 yrs

Reginald Van Genechten

TITLE
Head of Manufacturing & Supply Chain
AGE
53
TENURE
4.1 yrs

Erik Vossenaar

TITLE
Vice President of Business Development
AGE
46
TENURE
4.3 yrs
Board of Directors Tenure

Average tenure and age of the Biocartis Group board of directors in years:

2.6
Average Tenure
55
Average Age
  • The average tenure for the Biocartis Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Christian Reinaudo

TITLE
Independent Chairman of the Board
COMPENSATION
€47K
AGE
65
TENURE
1.9 yrs

Herman Verrelst

TITLE
CEO & Director
COMPENSATION
€510K
AGE
45
TENURE
2.6 yrs

Geert Maertens

TITLE
Chairman of Scientific Advisory Board & Chief Scientific Officer

Luc Gijsens

TITLE
Non-Executive Independent Director
COMPENSATION
€28K
AGE
65

Roald Borré

TITLE
Non-Executive Director
COMPENSATION
€36K
AGE
46
TENURE
5.3 yrs

Leo Steenbergen

TITLE
Non Executive Independent Director
COMPENSATION
€26K
AGE
66

Ann-Christine Sundell

TITLE
Non Executive Independent Director
COMPENSATION
€29K
AGE
55

Harry Glorikian

TITLE
Non Executive Independent Director
COMPENSATION
€27K
AGE
53

Eric Cutsem

TITLE
Member of Scientific Advisory Board

Josep Tabernero

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Biocartis Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biocartis Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry, with a focus on oncology in Belgium and internationally. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information allowing treatment selection and treatment progress monitoring. The company offers formalin fixed, paraffin embedded solid biopsy tests, including diagnostic products, such as Idylla BRAF, KRAS, NRAS-BRAF, NRAS, and EGFR mutation tests; and research products, which include Idylla MSI and NRAS-BRAF-EGFR S492R mutation assays. It also provides plasma liquid biopsy tests comprising diagnostic products that include Idylla ctKRAS and ctNRAS-BRAF mutation tests; and research products consisting of Idylla ctBRAF and ctNRAS-BRAF-EGFR S492R mutation assays. The company has collaboration agreement with AstraZeneca to develop and commercialize Idylla based molecular tests in support of AstraZeneca’s pharmaceutical products. Biocartis Group NV was founded in 2007 and is headquartered in Mechelen, Belgium.

Details
Name: Biocartis Group NV
BCARTB
Exchange: BATS-CHIXE
Founded: 2007
€198,464,949
56,382,088
Website: http://www.biocartis.com
Address: Biocartis Group NV
Generaal De Wittelaan 11 B3,
Mechelen,
Antwerp, 2800,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR BCART New Ordinary Shares Euronext Brussels BE EUR 27. Apr 2015
DB 8XB New Ordinary Shares Deutsche Boerse AG DE EUR 27. Apr 2015
LSE 0R72 New Ordinary Shares London Stock Exchange GB EUR 27. Apr 2015
BATS-CHIXE BCARTB New Ordinary Shares BATS 'Chi-X Europe' GB EUR 27. Apr 2015
Number of employees
Current staff
Staff numbers
448
Biocartis Group employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 19:54
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/03/06
Last earnings filing: 2020/03/05
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.